Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tirzepatide: In the SURMOUNT-1 trial, participants saw an average weight loss of up to 22.5%
The clinical data is consistent
Patients needing more aggressive weight reduction (20%+ body weight loss) are likely better served by tirzepatide or future triple-agonist therapies like retatrutide that produce higher average weight loss
Timing Baseline Marker Comprehensive metabolic panel (CMP) Why it matters Reviews liver and kidney markers, which matter for systemic exposure and copper handling context
US$ 23.66
US$ 29.83
US$ 26.20
US$ 23.30
US$ 23.33
US$ 28.56
US$ 27.26
